The Clinical Presentation, Survival Outcomes, and Management of Patients With Renal Cell Carcinoma and Cardiac Metastasis Without Inferior Vena Cava Involvement: Results From a Pooled Clinical Trial Database and Systematic Review of Reported Cases.

Autor: Viteri Malone MA; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA., Ares GR; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA., De Velasco G; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA., Brandão R; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA., Lin X; Pfizer Oncology, New York, NY., Norton C; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA., Simantov R; Pfizer Oncology, New York, NY., Moslehi J; Cardio-Oncology Program, Division of Cardiovascular Medicine, Department of Medicine, Vanderbilt University, Nashville, TN., Krajewski KM; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA., Choueiri TK; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA., McKay RR; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA; Department of Medicine, Division of Hematology/Oncology, University of California, San Diego, La Jolla, CA. Electronic address: rmckay@ucsd.edu.
Jazyk: angličtina
Zdroj: Clinical genitourinary cancer [Clin Genitourin Cancer] 2018 Apr; Vol. 16 (2), pp. e327-e333. Date of Electronic Publication: 2017 Dec 06.
DOI: 10.1016/j.clgc.2017.11.005
Abstrakt: Background: Cardiac metastases from renal cell carcinoma (RCC) are uncommon and there are limited data regarding the presentation and outcomes of this population. The objective of this study was to evaluate the characteristics and outcomes of patients with RCC with cardiac metastasis without inferior vena cava (IVC) involvement.
Materials and Methods: We conducted a pooled retrospective analysis of metastatic RCC patients treated in 4 clinical trials. Additionally, we conducted a systematic review of cases reported in the literature from 1973 to 2015. Patients with cardiac metastases from RCC without IVC involvement were included. Patient and disease characteristics were described. Additionally, treatments, response to therapy, and survival outcomes were summarized.
Results: Of 1765 metastatic RCC patients in the clinical trials database, 10 had cardiac metastases without IVC involvement. All patients received treatment with targeted therapy. There was 1 observed partial response (10%) and 6 patients showed stable disease (60%). The median progression-free survival was 6.9 months. The systematic review of reported clinical cases included 39 patients. In these patients, the most common cardiac site of involvement was the right ventricle (51%; n = 20). Patients were treated with medical (28%; n = 11) and/or surgical treatment (49%; n = 19) depending on whether disease was isolated (n = 13) or multifocal (n = 26).
Conclusion: To our knowledge, this is the first series to report on the presentation and outcomes of patients with cardiac metastasis without IVC involvement in RCC. We highlight that although the frequency of patients with cardiac metastases without IVC involvement is low, these patients have a unique clinical presentation and warrant special multidisciplinary management.
(Copyright © 2017 Elsevier Inc. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: